Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry A Greenbaum

Showing results (71-80 of 170) with videos related to

Pageof 17
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|October 8, 2011
Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney diseaseAmy C Wilson, Michael F Schneider, Christopher Cox, et al.
BMC Nephrology|June 1, 2017
Approach to growth hormone therapy in children with chronic kidney disease varies across North America: the Midwest Pediatric Nephrology Consortium reportOleh M Akchurin, Amy J Kogon, Juhi Kumar, et al.
Pediatric Nephrology (Berlin, Germany)|January 22, 2013
Restless legs syndrome in children with chronic kidney diseaseSandeep K Riar, Roberta M Leu, Taieshia C Turner-Green, et al.
Kidney International|June 22, 2023
Corrigendum to "The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2021;100:225-237Gema Ariceta, Bradley P Dixon, Seong Heon Kim, et al.
Kidney International|December 11, 2020
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatmentGema Ariceta, Bradley P Dixon, Seong Heon Kim, et al.
Pediatric Nephrology (Berlin, Germany)|March 10, 2015
Kidney transplantation in children with decreased left ventricular systolic function: a Midwest Pediatric Nephrology Consortium studySandeep K Riar, Mark M Mitsnefes, Edward J Nehus, et al.
Nephrology (Carlton, Vic.)|April 11, 2024
Characterization of patients with aHUS and associated triggers or clinical conditions: A Global aHUS Registry analysisChristoph Licht, Imad Al-Dakkak, Katerina Anokhina, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 21, 2020
Infection-Related Acute Care Events among Patients with Glomerular DiseaseDorey A Glenn, Candace D Henderson, Michelle O'Shaughnessy, et al.
Frontiers in Pediatrics|July 25, 2022
Collapsing Focal Segmental Glomerulosclerosis in Siblings With Compound Heterozygous Variants in <i>NUP93</i> Expand the Spectrum of Kidney Phenotypes Associated With Nucleoporin Gene MutationsRachel K Cason, Anna Williams, Megan Chryst-Stangl, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 30, 2010
The association between abnormal birth history and growth in children with CKDLarry A Greenbaum, Alvaro Muñoz, Michael F Schneider, et al.
Pageof 17

Showing results (71-80 of 170) with videos related to

Sort By:
Pageof 17
Clinical Journal of the American Society of Nephrology : CJASN|October 8, 2011
Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney diseaseAmy C Wilson, Michael F Schneider, Christopher Cox, et al.
BMC Nephrology|June 1, 2017
Approach to growth hormone therapy in children with chronic kidney disease varies across North America: the Midwest Pediatric Nephrology Consortium reportOleh M Akchurin, Amy J Kogon, Juhi Kumar, et al.
Pediatric Nephrology (Berlin, Germany)|January 22, 2013
Restless legs syndrome in children with chronic kidney diseaseSandeep K Riar, Roberta M Leu, Taieshia C Turner-Green, et al.
Kidney International|June 22, 2023
Corrigendum to "The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2021;100:225-237Gema Ariceta, Bradley P Dixon, Seong Heon Kim, et al.
Kidney International|December 11, 2020
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatmentGema Ariceta, Bradley P Dixon, Seong Heon Kim, et al.
Pediatric Nephrology (Berlin, Germany)|March 10, 2015
Kidney transplantation in children with decreased left ventricular systolic function: a Midwest Pediatric Nephrology Consortium studySandeep K Riar, Mark M Mitsnefes, Edward J Nehus, et al.
Nephrology (Carlton, Vic.)|April 11, 2024
Characterization of patients with aHUS and associated triggers or clinical conditions: A Global aHUS Registry analysisChristoph Licht, Imad Al-Dakkak, Katerina Anokhina, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 21, 2020
Infection-Related Acute Care Events among Patients with Glomerular DiseaseDorey A Glenn, Candace D Henderson, Michelle O'Shaughnessy, et al.
Frontiers in Pediatrics|July 25, 2022
Collapsing Focal Segmental Glomerulosclerosis in Siblings With Compound Heterozygous Variants in <i>NUP93</i> Expand the Spectrum of Kidney Phenotypes Associated With Nucleoporin Gene MutationsRachel K Cason, Anna Williams, Megan Chryst-Stangl, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 30, 2010
The association between abnormal birth history and growth in children with CKDLarry A Greenbaum, Alvaro Muñoz, Michael F Schneider, et al.
Pageof 17